Results 221 to 230 of about 22,016,000 (350)
Molecular Oncology, EarlyView.AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Current and future uses of biometric data and technologies. Sixth Report of Session 2014-15: Report, together with formal minutes relating to the report [PDF]
, 2015 House of Commons, Science and Technology Committee
core
On the Problem and Promise of Metaphor Use in Science and Science Communication. [PDF]
J Microbiol Biol Educ, 2018 Taylor C, Dewsbury BM.
europepmc +1 more source
Walailak Journal of Science and Technology, 2011 Walailak Journal of Science and Technology
doaj +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
The bioengineered kidney: science or science fiction? [PDF]
Curr Opin Nephrol Hypertens, 2016 Oxburgh L, Carroll TJ.
europepmc +1 more source
Molecular Oncology, EarlyView.This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source